DK1230354T3 - Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer - Google Patents

Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer

Info

Publication number
DK1230354T3
DK1230354T3 DK00979539T DK00979539T DK1230354T3 DK 1230354 T3 DK1230354 T3 DK 1230354T3 DK 00979539 T DK00979539 T DK 00979539T DK 00979539 T DK00979539 T DK 00979539T DK 1230354 T3 DK1230354 T3 DK 1230354T3
Authority
DK
Denmark
Prior art keywords
die
generation
amniozyten
der
von
Prior art date
Application number
DK00979539T
Other languages
English (en)
Inventor
Stefan Kochanek
Gudrun Schiedner
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK1230354T3 publication Critical patent/DK1230354T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • C12N2710/10352Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405Vectors comprising RGD peptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018Adenoviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
DK00979539T 1999-11-18 2000-11-07 Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer DK1230354T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19955558A DE19955558C2 (de) 1999-11-18 1999-11-18 Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren

Publications (1)

Publication Number Publication Date
DK1230354T3 true DK1230354T3 (da) 2004-03-22

Family

ID=7929523

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00979539T DK1230354T3 (da) 1999-11-18 2000-11-07 Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer

Country Status (16)

Country Link
EP (1) EP1230354B1 (da)
JP (1) JP4456790B2 (da)
CN (1) CN100412201C (da)
AT (1) ATE257512T1 (da)
AU (1) AU784003B2 (da)
CA (1) CA2391591C (da)
CZ (1) CZ300124B6 (da)
DE (2) DE19955558C2 (da)
DK (1) DK1230354T3 (da)
ES (1) ES2211647T3 (da)
HU (1) HU227440B1 (da)
IL (2) IL149291A0 (da)
PL (1) PL205966B1 (da)
PT (1) PT1230354E (da)
TR (1) TR200400402T4 (da)
WO (1) WO2001036615A2 (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
EP1718738A2 (en) 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
FI2061803T4 (fi) 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
DE102009003439A1 (de) 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
CA2776461C (en) 2009-10-15 2020-08-25 Crucell Holland B.V. Method for the purification of adenovirus particles.
JP5465331B2 (ja) 2009-10-15 2014-04-09 クルセル ホランド ベー ヴェー 高細胞密度の培養物からのアデノウイルスの精製方法
DK2536829T3 (da) 2010-02-15 2016-07-04 Crucell Holland Bv Fremgangsmåde til produktion af Ad26-adenovirusvektorer
MX337687B (es) 2010-08-16 2016-03-15 Cevec Pharmaceuticals Gmbh Linea celular de amniocitos humanos permanente para la produccion de virus de influenza.
KR101427200B1 (ko) * 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
KR102050616B1 (ko) 2012-03-22 2019-12-03 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
EP2662451A1 (en) 2012-05-07 2013-11-13 Stefan Kochanek Nucleic acid construct and use of the same
US20150259387A1 (en) * 2012-10-19 2015-09-17 Cevec Pharmaceuticals Gmbh Production of a hcmv based vaccine in human amniocyte cell lines
EP2722337A1 (en) * 2012-10-19 2014-04-23 CEVEC Pharmaceuticals GmbH Production of a HCMV based vaccine in human amniocyte cell lines
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 rsv f 폴리펩타이드
AP2015008893A0 (en) 2013-06-17 2015-12-31 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
WO2015000856A1 (de) 2013-07-01 2015-01-08 Charité - Universitätsmedizin Berlin Immortalisierte humane chorionzelllinie sowie verfahren zur immortalisierung humaner chorionzellen
MX2017005788A (es) 2014-11-04 2017-08-02 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el vph16.
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
EP3283634B1 (en) 2015-04-14 2019-05-22 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
US10456462B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
CN107921110B (zh) 2015-08-20 2021-10-15 扬森疫苗与预防公司 治疗性hpv18疫苗
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CA3021341A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
BR112018072865A2 (pt) 2016-05-12 2019-04-30 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
PL3464331T3 (pl) 2016-05-30 2021-04-19 Janssen Vaccines & Prevention B.V. Stabilizowane przedfuzyjne białka F RSV
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
CA3053212C (en) 2017-02-09 2021-04-13 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
BR112020004143A2 (pt) 2017-09-15 2020-09-01 Janssen Vaccines & Prevention B.V. método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
SG11202003399TA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
BR112020008435A2 (pt) 2017-10-31 2020-11-17 Janssen Vaccines & Prevention B.V. vetores de adenovírus e seus usos
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
KR20200083510A (ko) 2017-10-31 2020-07-08 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 및 이의 용도
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
AU2020275910A1 (en) 2019-05-15 2021-11-04 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
WO2020229577A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021043757A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
US20220372515A1 (en) 2019-10-03 2022-11-24 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
IL302046A (en) 2020-10-15 2023-06-01 Hoffmann La Roche Nucleic acid structures for va RNA transcription
KR20230085170A (ko) 2020-10-15 2023-06-13 에프. 호프만-라 로슈 아게 동시 유전자 활성화를 위한 핵산 구조체
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
WO2023227438A1 (en) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Raman-based method for the differentiation of aav particle serotype and aav particle loading status
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0833934T2 (sl) * 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji

Also Published As

Publication number Publication date
CA2391591C (en) 2008-12-30
PL357495A1 (en) 2004-07-26
DE19955558A1 (de) 2001-06-07
ES2211647T3 (es) 2004-07-16
IL149291A (en) 2008-11-26
PT1230354E (pt) 2004-04-30
JP2003514526A (ja) 2003-04-22
CN100412201C (zh) 2008-08-20
IL149291A0 (en) 2002-11-10
JP4456790B2 (ja) 2010-04-28
HU227440B1 (en) 2011-06-28
WO2001036615A2 (de) 2001-05-25
PL205966B1 (pl) 2010-06-30
HUP0203387A2 (hu) 2002-12-28
EP1230354A2 (de) 2002-08-14
EP1230354B1 (de) 2004-01-07
CA2391591A1 (en) 2001-05-25
DE19955558C2 (de) 2003-03-20
HUP0203387A3 (en) 2005-07-28
DE50004995D1 (de) 2004-02-12
CN1433476A (zh) 2003-07-30
CZ300124B6 (cs) 2009-02-18
WO2001036615A3 (de) 2002-01-10
AU784003B2 (en) 2006-01-12
ATE257512T1 (de) 2004-01-15
CZ20021709A3 (cs) 2002-08-14
AU1699001A (en) 2001-05-30
TR200400402T4 (tr) 2004-03-22

Similar Documents

Publication Publication Date Title
DK1230354T3 (da) Permanent amniocytcellelinje, frembringelse deraf og anvendelse deraf til frembringelse af genoverføringsvektorer
SE9900100D0 (sv) New compounds
MA26771A1 (fr) Benzoheterocycles et leur utilisation comme inhibiteurs de mek.
WO1998007830A3 (en) COMPLETE GENOME SEQUENCE OF THE METHANOGENIC ARCHAEON, $i(METHANOCOCCUS JANNASCHII)
DE60044298D1 (de) Ausflockung von zellmaterial
AU2001282008A1 (en) Method for accessing a cellular communication network
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
IT1264516B1 (it) Cellule dendritiche immortalizzate
DK1204659T3 (da) Serotonerge benzofuraner
TR199901386T2 (en) �midazopiridazinler.
ATE280169T1 (de) Serotonerge benzothiophene
WO2001059138A3 (en) Plant internal ribosome entry segment
ATE57917T1 (de) Hydroxipyrazol-derivate- verfahren zu ihrer herstellung und ihre verwendung gegen mikroorganismen.
ATE342998T1 (de) Replikation -defektive baculoviren expressionssystem
WO2000061729A3 (en) Regulation of the expression of transcriptional repressor genes using nucleic acid molecules
TR200100142T2 (tr) R-(+)-6-Karboksamido-3-N-Metilamino-1,2,3,4- tetrahidrokarbazol üretimi için işlem.
TR199700513A2 (xx) Reaktif aluminyumftalosiyanin boyar maddeleri, �retilmelerine mahsus usul ve bunlar�n kullan�lmas�.
BR0207647B1 (pt) processo de regulação de uma célula de eletrólise.
WO2000066787A3 (en) Growth hormone-regulatable liver genes and proteins, and uses thereof
FR2794541B1 (fr) Dispositif pour realiser une economie d'energie, pourvu d'une intelligence artificielle
Adamski Engineers of the Future: PEs or PhDs\= Bidders or Proposers
TR200001414A3 (tr) Yeni parlak sari florotriazin boyalari, bunlarin preparasyonu, kullanimi.
BG104401A (en) Chloroacetamide mixtures with suppressed precipitation
HU908102D0 (en) Process for stereoselective production of 1-bromine-3-chlorine,1,2-diaryl-2-propanoles in given case and their transformation into azolyl-methyl-oxiranes
DE50013406D1 (de) Unbunte lacke, verfahren zu ihrer herstellung und ihre verwendung